CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
N-acetylcysteine capsuledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02212678
NCT02212678Phase 2Completed
CompareCT.gov

Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

University of Minnesota·interventional·Posted Aug 8, 2014·Updated May 16, 2019

In Brief

A Phase 2 clinical trial evaluating N-acetylcysteine capsule for Parkinson Disease. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
CollaboratorsParkinson's Disease Society of the United Kingdom

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 8, 2014
Enrollment StartSep 1, 2014
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.9 years ago

Interventions

N-acetylcysteine capsuledrug

N-acetylcysteine capsule